drugset / Trial / NCT01391663

Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

NCT01391663

Phase 1 Completed 48 enrolled Takeda
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to assess the Pharmacokinetics and Pharmacodynamics of alogliptin after a single or multiple administrations, once daily (QD), of oral alogliptin in healthy Korean subjects.

Timeline

Start
2011-07
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 12.5 mg Oral
Subject Alogliptin Unknown 25 mg Oral
Subject Alogliptin Unknown 50 mg Oral

Indications

No indication recorded.